Quintrio
Home

Stock overview

XORTX Therapeutics Inc. Common Stock

XRTX

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Last trade $0.9801
Day change -$0.0599 (-5.76%)
Day range $0.9208 – $1.03
Volume 45,101
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for XRTX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for XRTX.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

XORTX Patent Allowed for XRx-101 Program by Japan Patent Office

XORTX Therapeutics announced that the Japan Patent Office has issued a Decision to Grant a patent for its xanthine oxidase inhibitor compositions (XRx-101) for treating acute kidney injury and other health consequences of viral infections. The patent, expected to remain in force until March 2041, marks the company's first patent protection in Japan and strengthens its intellectual property position in one of the world's largest pharmaceutical markets.

GlobeNewswire Inc.

XORTX Announces Termination and Postponement of Investor Relations Program

XORTX Therapeutics has terminated its US$2.5 million investor relations and marketing agreement with IR Agency LLC effective August 7, 2026, with all funds returned to the company. The decision was made to postpone the IR program during the company's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. The company aims to reduce regulatory complexity and focus resources on clinical development. Additionally, XORTX disclosed previously omitted finder's fees of US$240,000 related to its April 2026 acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program.

GlobeNewswire Inc.

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV) to reduce costs and administrative burden. The company will maintain its listings on Nasdaq and Frankfurt. The delisting is expected to eliminate duplicative exchange fees, reduce legal and accounting expenses, and allow management to focus on advancing its XRx-026 gout treatment program. Canadian shareholders will retain full trading access on Nasdaq.

GlobeNewswire Inc.

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

XORTX Therapeutics has completed its acquisition of the VB4-P5 program from Vectus Biosystems, a novel therapeutic targeting kidney fibrosis in chronic kidney disease. The deal valued at US$3.0 million includes patent rights and preclinical data. VB4-P5 is positioned to address a significant unmet medical need in both rare and prevalent kidney diseases affecting millions globally.

GlobeNewswire Inc.

XORTX Confirms Effective Date of Share Consolidation

XORTX Therapeutics announced that its 1-for-5 share consolidation has received all required approvals from TSX Venture Exchange and Nasdaq Stock Exchange, effective April 6, 2026. The company is a late-stage clinical pharmaceutical firm developing therapies for gout and progressive kidney disease, with three clinically advanced products in development.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 6, 20261-for-5reverse split
Nov 14, 20231-for-9reverse split